Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial

Targeted Oncology

Volumn 11, Issue 5, 2016, Pages 619-629

  Arrieta, Oscar ^a   Cruz Rico, Graciela ^a   Soto Perez de Celis, Enrique ^b   Ramírez Tirado, Laura Alejandra ^a   Caballe Perez, Enrique ^a   Martínez Hernández, Jorge Negueb ^a   Martinez Alvarez, Ivan ^a   Soca Chafre, Giovanny ^a   Macedo Pérez, Eleazar Omar ^a   Astudillo de la Vega, Horacio ^c  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; SCATTER FACTOR; VASCULOTROPIN RECEPTOR; QUINAZOLINE DERIVATIVE; RADIOSENSITIZING AGENT;

ACNE; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG RESPONSE; DRUG WITHDRAWAL; EGFR GENE; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL TIME; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 84962197460     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0425-x     Document Type: Article

References (54)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.29210.
2. Arrieta O, Campos-Parra AD, Zuloaga C, Aviles A, Sanchez-Reyes R, Manriquez ME, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7(8):1228–34. doi:10.1097/JTO.0b013e3182582a93.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2007;2(8):706–14. doi:10.1097/JTO.0b013e31812f3c1a.
4. Arrieta O, Guzman-de Alba E, Alba-Lopez LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, et al. National consensus of diagnosis and treatment of non-small cell lung cancer. Rev Investig Clin Organo Hosp Enferm Nutr. 2013;65 Suppl 1:S5–84.
5. Campos-Parra AD, Cruz-Rico G, Arrieta O. Personalized treatment in non-small cell lung cancer. Rev Investig Clin Organo Hosp Enferm Nutr. 2012;64(4):377–86.
6. Okamoto I, Mitsudomi T, Nakagawa K, Fukuoka M. The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. Ther Adv Med Oncol. 2010;2(5):301–7. doi:10.1177/1758834010370698.
7. Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009;14(11):1116–30. doi:10.1634/theoncologist.2009-0054.
8. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi:10.1056/NEJMra0802714.
9. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(21):2866–74. doi:10.1200/JCO.2010.33.4235.
10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. doi:10.1056/NEJMoa0810699.
11. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–8. doi:10.1016/S1470-2045(15)00026-1.
12. Arrieta O, Anaya P, Morales-Oyarvide V, Ramirez-Tirado LA, Polanco AC. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. Eur J Health Econ HEPAC Health Econ Prev Care. 2015. doi:10.1007/s10198-015-0726-5.
13. Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sanchez-Reyes R, Amieva-Rivera E, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer. 2015;87(2):169–75. doi:10.1016/j.lungcan.2014.12.009.
14. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92. doi:10.1056/NEJMoa044238.
15. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73. doi:10.1371/journal.pmed.0020073.
16. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi:10.1126/scitranslmed.3002003.
17. Canadas I, Rojo F, Taus A, Arpi O, Arumi-Uria M, Pijuan L, et al. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(4):938–50. doi:10.1158/1078-0432.CCR-13-1330.
18. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 1997;57(15):3305–13.
19. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17(1):77–88. doi:10.1016/j.ccr.2009.11.022.
20. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68(22):9479–87. doi:10.1158/0008-5472.CAN-08-1643.
21. Keating GM. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs. 2014;74(2):207–21. doi:10.1007/s40265-013-0170-8.
22. Spicer JF, Rudman SM. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol. 2010;5(4):245–55. doi:10.1007/s11523-010-0140-y.
23. De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123–7. doi:10.1016/j.lungcan.2012.01.008.
24. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–51. doi:10.1016/S1470-2045(14)71173-8.
25. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528–38. doi:10.1016/S1470-2045(12)70087-6.
26. Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, et al. Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Med Oncol. 2012;29(3):1614–21. doi:10.1007/s12032-011-0009-7.
27. Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer. 2011;74(2):293–9. doi:10.1016/j.lungcan.2011.02.021.
28. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(27):3327–34. doi:10.1200/JCO.2012.44.2806.
29. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22. doi:10.1016/S1470-2045(13)70604-1.
30. Blumenschein Jr GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(26):3287–96. doi:10.1200/JCO.2011.40.3774.
31. Takigawa N, Segawa Y, Maeda Y, Takata I, Fujimoto N. Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients. Lung Cancer. 1997;17(2-3):211–8.
32. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer J Int cancer. 2009;125(7):1657–62. doi:10.1002/ijc.24554.
33. Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H, Kusunoki M. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol. 2004;39(8):754–60. doi:10.1080/00365520410005973.
34. Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(22):7385–90. doi:10.1158/1078-0432.CCR-07-5110.
35. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Nord Myeloma Study Group Blood. 1998;91(3):806–12.
36. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J. Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neuro-Oncol. 2010;97(3):347–51. doi:10.1007/s11060-009-0037-8.
37. Arrieta O, Garcia E, Guevara P, Garcia-Navarrete R, Ondarza R, Rembao D, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002;94(12):3210–8. doi:10.1002/cncr.10594.
38. Martinez-Rumayor A, Arrieta O, Guevara P, Escobar E, Rembao D, Salina C, et al. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Lett. 2004;213(1):117–24. doi:10.1016/j.canlet.2004.04.026.
39. Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, et al. The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? Curr Drug Targets. 2014;15(14):1284–92.
40. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt Jr JH, Blumenschein Jr GR, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(32):4105–14. doi:10.1200/JCO.2012.47.4189.
41. Spigel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Shames DS, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb and IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol. 2014;32:5s (suppl; abstr 8000).
42. Perol M. Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC. Transl Lung Cancer Res. 2014;3(6):392–4. doi:10.3978/j.issn.2218-6751.2014.09.06.
43. Mok TT E, Greater SL, Chang G, Yang J, Gyuris J, Han M, et al., editors. 205P - Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic based subgroups of patients with previously untreated lung adenocarcinoma. Madrid: ESMO 2014; 2014.
44. Mok TET, Park K, Jac J, Han M, PayumoFC, Credi M, et al. Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(suppl; abstr TPS213).
45. Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther. 2010;9(10):2785–92. doi:10.1158/1535-7163.MCT-10-0481.
46. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(21):6630–8. doi:10.1158/1078-0432.CCR-09-1001.
47. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99. doi:10.1056/NEJMoa1411817.
48. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700–9. doi:10.1056/NEJMoa1413654.
49. Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O’Connell J, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015;26(7):1421–7. doi:10.1093/annonc/mdv186.
50. Platform ETO. Afatinib in NSCLC With HER2 Mutation (NICHE). ClinicalTrials.gov. 2015-. https://clinicaltrials.gov/ct2/show/NCT02369484. Accessed 1 Dec 2015.
51. Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2011;6(11):1955–9. doi:10.1097/JTO.0b013e31822f655f.
52. Arrieta O, Cardona AF, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G, et al. Updated Frequency of EGFR and KRAS Mutations in nonsmall-cell lung cancer in Latin America: The Latin-American consortium for the investigation of lung cancer (CLICaP). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(5):838–43. doi:10.1097/JTO.0000000000000481.
53. Arrieta O, Ramirez-Tirado LA, Baez-Saldana R, Pena-Curiel O, Soca-Chafre G, Macedo-Perez EO. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”. Lung Cancer. 2015;90(2):161–6. doi:10.1016/j.lungcan.2015.08.010.
54. Arrieta O, Rios Trejo MA, Michel RM. Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009;4(8):1043. doi:10.1097/JTO.0b013e3181ae2497.